Alkermes schizophrenia treatment meets main goals in late-stage study

Get real time updates directly on you device, subscribe now.

Alkermes schizophrenia treatment meets main goals in late-stage study

Alkermes schizophrenia treatment meets main goals in late-stage study
2018-11-30 12:06:06

(Reuters) – Alkermes Plc’s treatment for schizophrenia met the main goals in a late-stage study, with patients not gaining as much weight as those treated with commonly used antipsychotic drug olanzapine, the company said on Thursday.

The high incidence of weight gain due to treatment from olanzapine limits the drug’s clinical use, Alkermes said in a statement.

Weight gain is a common side effect of atypical antipsychotic medications such as olanzapine, sold by Eli Lilly as Zyprexa.

Schizophrenia is a chronic, severe and disabling brain disorder, marked by hallucinations and depression. About 2.4 million American adults suffer from the disorder.

The company said it plans to submit the marketing application to the U.S. Food and Drug Administration in mid-2019.

The company’s shares, which closed up 4.6 percent on Wednesday, were halted.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Anil D’Silva

Our Standards:The Thomson Reuters Trust Principles.

Images are for reference only.Images gathered automatic from google.All rights on the images are with their original owners.



Alkermes schizophrenia treatment meets main goals in late-stage study
2018-11-30 12:06:06

Images are for reference only.Images gathered automatic from google.All rights on the images are with their original owners.

Get real time updates directly on you device, subscribe now.

Comments
Loading...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More